Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:54:59 EST Sat 07 Mar 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

C:BNXT - BioNxt Solutions Inc. - https://bionxt.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BNXT - C  6.50.56·0.607.00.57-0.02-3.45.8370.57  0.57  0.571.10  0.3813:16:06Feb 2715 min RT 2¢
CSE - C6.50.56·0.607.00.59-0.02-3.35.2350.57  0.57  0.571.10  0.3809:30:0015 min
NEO ATS - U 0.57-0.02-3.40.5010.57  0.57  0.5713:16:0615 min
MatchNOW - M 0.590.11    15 min

Recent Trades - All 7 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
13:16:06M0.57-0.021072 RBC1 AnonymousE
13:16:06U0.57-0.025002 RBC2 RBCK
09:30:00C0.58-0.0120036 Latimer1 AnonymousE
09:30:00C0.57-0.021,0001 Anonymous1 AnonymousK
09:30:00C0.57-0.021,0001 Anonymous1 AnonymousK
09:30:00C0.57-0.021,0001 Anonymous1 AnonymousK
09:30:00C0.57-0.022,0001 Anonymous1 AnonymousK
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2026-02-27 20:03C:BNXT0.63News ReleaseBionxt hires McMeekin, Cayo for IR services
2026-02-27 04:52C:BNXT0.60News ReleaseBionxt issues six million shares for debt of $2.7M
2026-02-17 11:33C:BNXT0.59News ReleaseBionxt obtains European patent for MS drug tech
2026-02-05 14:41C:BNXT0.58News ReleaseBionxt signs LOI for rights to drug chaperone technology
2026-01-26 11:33C:BNXT0.55News ReleaseBionxt moves cladribine ODF to clinic
2026-01-23 16:11C:BNXT0.45News ReleaseBionxt Solutions to issue six million shares for debt
2026-01-21 14:32C:BNXT0.48News ReleaseBionxt talks cladribine preclinical pig study results
2026-01-19 12:36C:BNXT0.485News ReleaseBionxt discusses cladribine ODF study
2025-12-17 10:59C:BNXT0.65News ReleaseBionxt Solutions talks up sublingual thin-film product
2025-12-09 10:28C:BNXT0.68News ReleaseBionxt working on melt-in-your-mouth cladribine product
2025-12-01 14:42C:BNXT0.65News ReleaseBionxt to acquire IP to sublingual drug formulation
2025-11-28 15:00C:BNXT0.67SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-11-28 15:00C:BNXT0.67SEDAR Interim MD & ASEDAR Interim MD & A
2025-11-20 13:30C:BNXT0.66News ReleaseBionxt Solutions receives Eurasian patent grant
2025-11-04 11:51C:BNXT0.83News ReleaseBionxt receives EU patent grant notice for oral MS film
2025-10-30 10:45C:BNXT0.83News ReleaseBionxt receives EAPO readiness-to-grant notification
2025-10-23 13:26C:BNXT0.85News ReleaseBionxt reiterates BNT23001 dosing optimization study
2025-10-21 10:14C:BNXT0.84News ReleaseBionxt begins BNT23001 animal bioequivalence study
2025-10-14 14:54C:BNXT0.91News ReleaseCSE Bulletin: MOC Eligibility Update
2025-10-09 19:50C:BNXT0.87News ReleaseBioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities